Akorn Sees A $10m Increase In FDA Compliance Expenditure

 
• By Akriti Seth

Akorn’s second-quarter results show a drop in sales despite the launch of three new products. The company expects a $10m increase in FDA compliance and data-integrity assessment expenditures because of a warning letter issued over its Somerset manufacturing facility.

Unsuccessful -Businessman
Increased cost in FDA compliance and settlement of shareholder lawsuits reflect in Akorn’s Q2 FY19 results • Source: Shutterstock

More from Strategy

More from Business